Clinical trials: Fungemia
Candidemia Prognostic Factor and Mycobiological Analysis.
The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia
Candida albicans is the most common and important clinical fungal pathogen. Our previous surveillance disclosed that fluconazole could induce different morphological changes in clinical strains. Our current study on C.
- Trial name
- NCT01211041
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Fungemia, Mycoses
Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients
The aim of the study is to determine viable use of caspofungin in post-OLTx patients, and to demonstrate in particular the effectiveness, understood as the ability to reduce the incidence of invasive fungal infections, and to…
- Trial name
- CPHRLTX (NCT01260974)
- Testing
- Caspofungin
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Azienda Ospedaliera di Padova
Candidemia
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
The purpose of this pharmacokinetic (PK) and pharmacodynamic (PD) study is: To study the rate and duration of serum cidal activity of caspofungin (CFG) and micafungin (MFG) against Candida isolates from the subject and against…
- Trial name
- NCT00839540
- Testing
- micafungin, Caspofungin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gary E. Stein, Pharm.D.
Fever, Mycoses
Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia
The objective of this study is to evaluate the safety, tolerance, and pharmacokinetics of FK463, a novel echinocandin (cell wall-active antifungal lipopeptide), as early empirical therapy for prevention of fungal infections in…
- Conditions
- Fever, Mycoses, Neutropenia
- Trial name
- NCT00001790
- Testing
- FK463
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Candidemia
Candidemia in a Pediatric Center and Importance of Central Venous Catheter Removal
Candidemia has emerged as an important cause of hospital-associated blood-stream infection in children. The purpose of this study was to identify differences in distribution of candida species, risk factors, treatment, and…
- Trial name
- NCT02088476
- Where
- Turkey (Türkiye)
- Volunteers
- 248 people
- Sponsor
- Hacettepe University
Candidemia
Serial Therapeutic and Antifungal Monitoring Protocol
The objective of this study is to investigate T2Candida performance as a monitoring tool for post-therapy clearance of Candida compared to blood culture.
- Trial name
- STAMP (NCT02163889)
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- T2 Biosystems
Aspergillosis, Candidiasis
Voriconazole to Prevent Systemic Fungal Infections in Children
This study will examine how children's bodies metabolize and eliminate the anti-fungal drug voriconazole. The results will yield information needed to make recommendations for safe and effective dosing of the drug in children.
- Conditions
- Aspergillosis, Candidiasis, Fungal Diseases, Mycoses
- Trial name
- NCT00005912
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Candidemia, Candidiasis
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients with proven or probable fungal infections caused by Candida sp.
- Trial name
- NCT01982071
- Testing
- Micafungin
- Where
- 15 sites in China
- Volunteers
- 59 people
- Sponsor
- Astellas Pharma China, Inc.
Candidemia, Candidiasis, Invasive
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection…
- Trial name
- NCT05421858
- Testing
- Fosmanogepix, Caspofungin, Fluconazole
- Where
- 146 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Basilea Pharmaceutica
Fungemia, Fungal Infections
A Study to Compare Efficacy and Safety of Mycamine® and Itraconazole for Preventing Fungal Infections
The objective of this study is to compare the efficacy and safety between Mycamine and Itraconazole oral solution in preventing invasive fungal infections on autologous(malignant blood diseases) or allogeneic hematopoietic stem…
- Trial name
- NCT00794703
- Testing
- micafungin (Mycamine), itraconazole
- Where
- 10 sites in China
- Volunteers
- 288 people
- Sponsor
- Astellas Pharma Inc
Candidiasis
Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.
- Trial name
- NCT01202253
- Testing
- anidulafungin
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Pfizer
Candidiasis
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Anidulafungin is a medicine being developed for treatment of patients with certain kinds of fungal infections. These infections due to yeast (a type of fungus) in the mouth/esophagus, in the blood or in other areas within the…
- Trial name
- NCT00056368
- Testing
- Anidulafungin, Fluconazole
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- Pfizer
Candidemia
Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis
Prospective, open label study to assess the pharmacokinetics, safety \& efficacy of anidulafungin when used to treat children (aged 1 month - <18 years) with invasive candidiasis, including candidemia (ICC).
- Trial name
- NCT00761267
- Testing
- Anidulafungin, Fluconazole
- Where
- 45 sites in United States, Brazil and 8 more
- Volunteers
- 70 people
- Sponsor
- Pfizer
Candidiasis
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or…
- Trial name
- NCT00106288
- Testing
- Micafungin, Liposomal Amphotericin B
- Where
- 37 sites in United States, Canada
- Volunteers
- 637 people
- Sponsor
- Astellas Pharma Inc
Sepsis, Bacteremia
Clinical Evaluation of Novel Biomarkers in Patients With Septicemia
The protein ST2 is a member of the interleukin-1 receptor family. Blood concentrations of the soluble isoform of ST2 (sST2) are increased in inflammatory and heart diseases and are considered a prognostic marker in both.
- Conditions
- Sepsis, Bacteremia, Fungemia
- Trial name
- NOBIS (NCT01359891)
- Where
- Austria
- Volunteers
- 750 people
- Sponsor
- Medical University of Graz
Candidiasis
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose of the study is to find the balance between dose tolerance and effectiveness of several doses for the treatment of United States…
- Trial name
- NCT00037219
- Testing
- Anidulafungin, VER002
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Pfizer
Invasive Candidiasis
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
This is a single center, prospective, open label assessment of β-D-glucan surveillance with preemptive anidulafungin therapy versus standard care for the prevention of invasive candidiasis in at-risk surgical intensive care unit…
- Trial name
- NCT00672841
- Testing
- Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Duke University
Candida Fungemia
Retrospective Chart Review of Candida Fungemia
Background: Candida can cause infections. The most common kind of Candida at clinics is C albicans. But other kinds have increased at clinics too.
- Trial name
- NCT03827330
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Fungal
Dosage of Plasma 1, 3-β-D-glucan for the Diagnosis of Candidemia.
Systematic and repeated dosing (3 times weekly) of 1,3-β-D-glucan (BDG), associated with blood cultures and fungal mapping (twice a week) for the patients hospitalized in intensive care.
- Trial name
- BDG-REA (NCT03674359)
- Testing
- BDG analysis
- Where
- 2 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mycoses, Candidiasis, Invasive
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis.
- Conditions
- Mycoses, Candidiasis, Invasive, Candidemia
- Trial name
- NCT02244606
- Testing
- SCY-078, Fluconazole, Micafungin
- Where
- 30 sites in United States, El Salvador and 3 more
- Volunteers
- 27 people
- Sponsor
- Scynexis, Inc.